Evidence map›Paper›PMID 34818550›Full record

ArticleCell reports2021

Differentiation of fetal hematopoietic stem cells requires ARID4B to restrict autocrine KITLG/KIT-Src signaling.

In-Chi Young, Bogang Wu, Jaclyn Andricovich, Sung-Ting Chuang, Rong Li, Alexandros Tzatsos, Ray-Chang Wu, Mei-Yi Wu

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Dynamic Tracking of Native Precursors in Adult Mice.bioRxiv : the preprint server for biology · 2024
    Article
  9. CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities inInternational journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

In-Chi YoungDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Bogang WuDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Jaclyn AndricovichDepartment of Anatomy and Cell Biology, George Washington University, Washington, DC 20037, USA; George Washington University Cancer Center, George Washington University, Washington, DC 20037, USA.
Sung-Ting ChuangDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Rong LiDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Alexandros TzatsosDepartment of Anatomy and Cell Biology, George Washington University, Washington, DC 20037, USA; George Washington University Cancer Center, George Washington University, Washington, DC 20037, USA.
Ray-Chang WuDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA. Electronic address: rwu@gwu.edu.
Mei-Yi WuDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA; Department of Anatomy and Cell Biology, George Washington University, Washington, DC 20037, USA; Department of Medicine, George Washington University, Washington, DC 20037, USA. Electronic address: meiyiwu@gwu.edu.
George Washington University · US

Funding

Boosting Antitumor Immunity by Blocking Both Tumor and Adipose DDR1R01CA246707 · NCI · GEORGE WASHINGTON UNIVERSITY · PI LI, RONG · 2020 to 2024
$2.3M
Deregulation of COMPASS complex and enhancer chromatin in pancreatic cancerR01CA222930 · NCI · GEORGE WASHINGTON UNIVERSITY · PI TZATSOS, ALEXANDROS · 2018 to 2022
$1.8M
Corepressor Function of Steroid Receptor Coactivator-3 in Breast CancerR01CA188471 · NCI · GEORGE WASHINGTON UNIVERSITY · PI WU, RAY-CHANG · 2015 to 2019
$1.8M
Regulation of Type I Interferon Pro-tumor Effects in Breast CancerR01CA255996 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Mei-Yi Wu · 2021 to 2026
$1.8M
Steroid receptor coactivator-3 and cancer stem cellsR21CA187857 · NCI · GEORGE WASHINGTON UNIVERSITY · PI WU, RAY-CHANG · 2014 to 2015
$379k
NCI NIH HHS R01 CA188471NCI NIH HHS R01 CA222930NCI NIH HHS R01 CA246707NCI NIH HHS R01 CA255996NCI NIH HHS R21 CA187857
6 · The paper itself

Abstract

Balance between the hematopoietic stem cell (HSC) duality to either possess self-renewal capacity or differentiate into multipotency progenitors (MPPs) is crucial for maintaining homeostasis of the hematopoietic stem/progenitor cell (HSPC) compartment. To retain the HSC self-renewal activity, KIT, a receptor tyrosine kinase, in HSCs is activated by its cognate ligand KITLG originating from niche cells. Here, we show that AT-rich interaction domain 4B (ARID4B) interferes with KITLG/KIT signaling, consequently allowing HSC differentiation. Conditional Arid4b knockout in mouse hematopoietic cells blocks fetal HSC differentiation, preventing hematopoiesis. Mechanistically, ARID4B-deficient HSCs self-express KITLG and overexpress KIT. As to downstream pathways of KITLG/KIT signaling, inhibition of Src family kinases rescues the HSC differentiation defect elicited by ARID4B loss. In summary, the intrinsic ARID4B-KITLG/KIT-Src axis is an HSPC regulatory program that enables the differentiation state, while KIT stimulation by KITLG from niche cells preserves the HSPC undifferentiated pool.

Indexed as

AnimalsAutocrine CommunicationCell DifferentiationCell ProliferationCell Self RenewalDNA-Binding ProteinsFemaleHematopoiesisHematopoietic Stem CellsMaleMiceMice, Inbred C57BLMice, KnockoutProto-Oncogene Proteins c-kitSignal Transductionsrc-Family KinasesDNA-Binding ProteinsKit protein, mouseProto-Oncogene Proteins c-kitRbbp1l1 protein, mousesrc-Family KinasesStem Cell FactorTranscription FactorsARID4B, HSPC, HSC, MPP, KIT, KITLG

Identifiers

PMID34818550
PMCPMC8722094
OpenAlexW3215836714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.